📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Immunogenicity Summary Report (OBX-319)

Document ID: IMMUNO-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M10

Immunogenicity Summary Report — OBX-319

Anti-drug antibody (binding and neutralising) assessment is integral; immunogenicity may affect exposure and is characterised with a tiered validated assay strategy.

A tiered, validated assay strategy (screening, confirmatory, titre, and neutralising-antibody assays) was applied to samples from OBX319-301. The impact of anti-drug antibodies on exposure, efficacy, and safety was assessed and is summarised in Module 2.7.2.

OBX-319 is a humanized IgG1 anti-CD19 × anti-CD20 bispecific monoclonal antibody expressed in recombinant Chinese hamster ovary (CHO) cell culture, purified by a Protein A capture and polishing downstream train, and administered subcutaneously (SC) in moderate-to-severe active Systemic Lupus Erythematosus (SLE). As a therapeutic protein it carries an inherent potential to elicit anti-drug antibodies (ADA), and this report characterises the immunogenicity of OBX-319 in the pivotal Phase 3 study OBX319-301 (randomized, double-blind, placebo-controlled, 1:1:1, 52 weeks; N = 480 [162 OBX-319 High, 158 OBX-319 Low, 160 Placebo]) on background standard of care. The assessment integrates a risk-based immunogenicity strategy, a tiered and validated bioanalytical scheme validated to ICH M10, and an analysis of the clinical consequences of confirmed ADA on pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety. Because OBX-319 exhibits target-mediated drug disposition (TMDD), ADA that alter clearance can shift systemic exposure, so ADA status is carried as a covariate in the population PK analysis and is interpreted alongside the near-complete peripheral B-cell depletion that defines the pharmacology of this molecule. Consistent with the modality, this evaluation is developed within a Biologics License Application under 21 CFR 601, with the associated quality control strategy governed by ICH Q5A(R2)/Q5C/Q6B and the nonclinical package by ICH S6(R1) (cynomolgus monkey the sole pharmacologically relevant species, no rodent target cross-reactivity); standard small-molecule safety modules (genotoxicity, carcinogenicity, hERG/thorough-QT) are not warranted for a monoclonal antibody and do not bear on immunogenicity interpretation.

Regulatory basis and scope

The immunogenicity programme follows a risk-based lifecycle approach: a pre-clinical immunogenicity risk assessment, a validated tiered assay strategy, prospective sampling in the controlled clinical study, and an integrated evaluation of clinical impact. Bioanalytical validation of the ADA and neutralising-antibody (NAb) methods was performed under ICH M10, and results are reported using the standard immunogenicity terminology (pre-existing/baseline ADA, treatment-induced and treatment-boosted ADA, treatment-emergent ADA, transient versus persistent responses, titre, and neutralising status). The strategy is consistent with current health-authority immunogenicity expectations for therapeutic proteins (FDA and EMA immunogenicity guidance) and the labelling of observed immunogenicity in the USPI and SmPC. Assay descriptions and full validation data are provided in the bioanalytical method validation report (BIOANALYTICAL-001); the clinical-pharmacology integration and exposure–response context are provided in Module 2.7.2, and the safety integration in Module 2.7.4.

Immunogenicity risk assessment

The likelihood and clinical relevance of an ADA response reflect product-, treatment-, and patient-related factors, each of which was considered for OBX-319.

Product-related factors. OBX-319 is a humanized (predominantly human-framework) IgG1, which lowers the sequence-derived immunogenic potential relative to chimeric or murine constructs. As a bispecific, however, the molecule presents two distinct complementarity-determining-region (CDR) idiotypes (anti-CD19 and anti-CD20) and engineered junctional/interface sequences that constitute potential novel (neo-) epitopes not present in native human immunoglobulin; ADA can therefore arise against either binding arm, against framework/hinge determinants, or against the bispecific interface. Product-quality attributes that are recognised immunogenicity risk drivers — protein aggregate and subvisible-particle burden, high-molecular-weight species, CHO host-cell-protein and residual-DNA impurities, and charge/glycosylation heterogeneity — are controlled by the Protein A plus polishing purification train and the release/stability specifications set under ICH Q6B, with viral/adventitious-agent safety assured under ICH Q5A(R2) and stability under ICH Q5C. The SC formulation is surfactant-stabilised to minimise interfacial aggregation; no adjuvant is present.

Treatment- and route-related factors. SC administration and chronic dosing over the 52-week period were considered as factors that can favour ADA development relative to short-course intravenous exposure. Countervailing this, the intended pharmacology is directly immunosuppressive: simultaneous CD19 and CD20 engagement produces near-complete peripheral B-cell depletion (approximately 210 → 7 cells/µL on both active arms; essentially unchanged on placebo), and profound depletion of the B-lineage/antibody-secreting compartment is expected to blunt de novo humoral ADA formation. This mechanistic self-tolerance effect is an important interpretive consideration for the observed incidence.

Patient-related factors. The SLE population carries a high baseline burden of autoreactivity (antinuclear antibodies, anti-dsDNA, rheumatoid factor) and polyclonal B-cell hyperactivity, which can generate matrix interference and pre-existing reactivity in ADA assays; the tiered scheme and confirmatory specificity step were designed to distinguish drug-specific signal from this background. Background standard-of-care immunosuppression may further reduce the propensity to mount an ADA response.

Bioanalytical strategy — tiered, validated ADA assays

A multi-tier scheme was implemented and validated per ICH M10: screening → confirmatory (specificity) → titre → neutralising-antibody characterisation, supported by domain-resolved (idiotype-specific) characterisation appropriate to a bispecific.

Screening tier. A bridging electrochemiluminescence (ECL) format was used, in which ADA cross-link biotinylated and ruthenylated OBX-319 to generate signal. A statistically derived screening cut point targeting a 5% false-positive rate was applied to classify samples as potentially positive. Method sensitivity was established to meet the ICH M10 expectation (target sensitivity in the order of 100 ng/mL of a positive-control antibody), and drug tolerance was characterised so that the assay detects ADA at anticipated circulating drug concentrations; where required, an acid-dissociation pre-treatment step was incorporated to improve drug tolerance for a TMDD molecule with sustained trough exposure. A minimum required dilution was set to control SLE-matrix interference.

Confirmatory (specificity) tier. Screen-positive samples were confirmed by competitive inhibition with excess unlabelled OBX-319, using a confirmatory cut point targeting a 1% false-positive rate; only samples demonstrating drug-specific inhibition were reported as confirmed ADA-positive. This step is central to discriminating true anti-OBX-319 antibodies from the non-specific reactivity expected in an autoantibody-rich lupus matrix.

Titre tier. Confirmed-positive samples were serially diluted to an assay-defined endpoint to assign a titre, enabling magnitude and kinetic (rising/falling) characterisation of the response and supporting the transient-versus-persistent classification.

Neutralising-antibody tier. Confirmed ADA-positive samples were assessed for neutralising capacity. Given the mechanism (cell-surface CD19/CD20 engagement leading to B-cell depletion), a competitive ligand-binding NAb assay assessing inhibition of OBX-319 binding to its targets was used, with cell-based confirmation as appropriate; results were reported as neutralising or non-neutralising with associated titre.

Bispecific domain resolution. Because OBX-319 has two functional binding arms, confirmed-positive samples were further characterised for domain specificity — reactivity attributable to the anti-CD19 arm, the anti-CD20 arm, potential junctional/interface neo-epitopes, and shared framework/hinge determinants — to determine whether a response could selectively impair one binding function while sparing the other. Soluble-target (shed antigen) interference was evaluated and found to be limited, consistent with CD19 and CD20 being predominantly membrane-restricted antigens.

Sampling, populations, and analysis

ADA and NAb samples were collected at baseline (pre-dose) and at scheduled on-treatment visits across the 52-week double-blind period, with additional sampling at any hypersensitivity or injection/administration reaction and at early-discontinuation/follow-up visits to capture delayed responses. The ADA-evaluable population comprised subjects with a valid baseline result and at least one post-baseline ADA sample; it encompassed the 320 OBX-319–treated subjects (162 High, 158 Low) and the 160 placebo subjects. Baseline-positive subjects were tracked for treatment-boosting, and baseline-negative subjects for treatment-induced (treatment-emergent) responses. ADA status was time-matched to PK, PD (CD19+ B-cell counts), efficacy, and safety data to support the impact analyses, and was included as a clearance covariate in the population PK model described in Module 2.7.2.

Immunogenicity results (OBX319-301)

Treatment-emergent ADA incidence was low on both active arms and, consistent with the anticipated blunting of humoral responses by near-complete B-cell depletion, was numerically lower on the more deeply/durably depleting High-dose arm than on the Low-dose arm. Pre-existing (baseline) reactivity was infrequent and balanced across arms, in keeping with the confirmatory-tier control of lupus-matrix background.

Immunogenicity parameter	OBX-319 High (N = 162)	OBX-319 Low (N = 158)	Placebo (N = 160)
Treatment-emergent ADA (confirmed positive)	6.2% (10/162)	8.2% (13/158)	Not applicable
— Transient	7/10	9/13	—
— Persistent	1.9% (3/162)	2.5% (4/158)	—
Neutralising-antibody positive (of confirmed ADA-positive)	2	3	—

Onset and persistence. Treatment-emergent responses generally appeared within the first weeks to months of dosing and were predominantly transient (resolving on continued treatment). A minority of subjects had persistent ADA, and of these only a small number were neutralising; NAb titres were low, and neutralising responses were most often directed at a single binding arm rather than abrogating both functions simultaneously. Placebo subjects, by definition, had no treatment-emergent response to drug; sporadic assay reactivity in that arm reflected pre-existing/background signal rather than an induced anti-OBX-319 response.

Impact of ADA on pharmacokinetics

At the population level, ADA did not have a clinically meaningful effect on OBX-319 exposure. In the small subset of subjects with persistent and higher-titre ADA, increased clearance and correspondingly lower trough concentrations were observed, consistent with the ADA-positive covariate on clearance identified in the population PK analysis (Module 2.7.2). Because OBX-319 is governed by TMDD, this incremental ADA-mediated clearance operates alongside the saturable target-mediated pathway; the effect was confined to a minority of subjects and did not shift the overall exposure distribution or the dose rationale.

Impact of ADA on pharmacodynamics and efficacy

The primary pharmacodynamic effect — near-complete peripheral CD19+ B-cell depletion (approximately 210 → 7 cells/µL) — was achieved and sustained through Week 52 on both active arms irrespective of ADA status in the great majority of subjects; ADA did not produce a group-level attenuation or reversal of depletion, and isolated persistent, higher-titre responders were monitored for early B-cell repopulation. Efficacy was not materially affected by ADA status: the Week 52 low-disease-activity endpoint (SLEDAI-2K ≤ 4) was met by 52.4% (76/145) on OBX-319 High, 33.8% (49/145) on OBX-319 Low, and 6.0% (9/150) on Placebo, with corresponding LS-mean changes from baseline in SLEDAI-2K of −6.37 (High), −5.62 (Low), and −3.46 (Placebo) (placebo-adjusted differences −2.91 and −2.17), and the associated declines in anti-dsDNA and normalisation of complement C3/C4 among responders were preserved. The dual-antigen design provides functional redundancy against a single-arm neutralising response, supporting the maintenance of depletion despite low-level immunogenicity.

Impact of ADA on safety

No clinically meaningful safety consequence of immunogenicity was identified. Injection/administration and hypersensitivity reactions were infrequent and non-serious, no anaphylaxis was reported, and injection-site reactions were not driven by ADA status, consistent with SC delivery of a humanized IgG1. There was no association between ADA and the class-relevant identified risks of B-cell depletion (serious/opportunistic infection and hypogammaglobulinaemia). Immunogenicity is carried in the risk-management strategy and is reflected, with the observed low-level incidence and lack of clinical impact, in the product labelling.

Integrated assessment and conclusion

Treatment-emergent immunogenicity to OBX-319 was low-level, predominantly transient, infrequently neutralising, and — consistent with the humanized IgG1 modality and the self-limiting effect of profound B-cell depletion on humoral ADA formation — had no clinically meaningful impact on pharmacokinetics, pharmacodynamics (B-cell depletion), efficacy, or safety over the 52-week controlled period. Where a PK effect was detectable it was confined to a small subset of persistent, higher-titre responders and is captured by the ADA covariate in the population PK model, without altering the dose rationale or the favourable benefit–risk conclusion. Immunogenicity remains under routine surveillance, with the validated tiered assay strategy available for continued and post-marketing characterisation.

Guidelines: ICH M10 (bioanalytical/ADA method validation); supporting quality and nonclinical framework ICH Q5A(R2)/Q5C/Q6B and S6(R1); developed as a BLA under 21 CFR 601. Cross-references: M2.7.2 (clinical pharmacology, exposure–response, immunogenicity integration), M2.7.4 (clinical safety), BIOANALYTICAL-001 (assay validation).